Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Harvard Business School
Covington
Farmers Insurance
Novartis
QuintilesIMS
McKinsey
Johnson and Johnson
Citi
Mallinckrodt

Generated: August 17, 2017

DrugPatentWatch Database Preview

Bausch And Lomb Company Profile

« Back to Dashboard

What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?

BAUSCH AND LOMB has seventy-five approved drugs.

There are twenty-two US patents protecting BAUSCH AND LOMB drugs.

There are one hundred and forty-two patent family members on BAUSCH AND LOMB drugs in twenty-two countries.

Summary for Applicant: Bausch And Lomb

Patents:22
Tradenames:64
Ingredients:53
NDAs:75
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
OPTIPRANOLOL
metipranolol hydrochloride
SOLUTION/DROPS;OPHTHALMIC019907-001Dec 29, 1989ATRXYesYes► Subscribe► Subscribe► Subscribe
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872-001Sep 28, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
ISTALOL
timolol maleate
SOLUTION/DROPS;OPHTHALMIC021516-001Jun 4, 2004AT2RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
DIPIVEFRIN HYDROCHLORIDE
dipivefrin hydrochloride
SOLUTION/DROPS;OPHTHALMIC074188-001May 19, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
PENTOLAIR
cyclopentolate hydrochloride
SOLUTION/DROPS;OPHTHALMIC040075-001Apr 29, 1994ATRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAUSCH AND LOMB drugs

Drugname Dosage Strength Tradename Submissiondate
bepotastine besilate
Ophthalmic Solution1.5%
BEPREVE
9/9/2013
bromfenac sodium
Ophthalmic Solution0.07%
PROLENSA
7/26/2013
timolol maleate
Ophthalmic Solution0.5%
ISTALOL
10/19/2012

Non-Orange Book Patents for Bausch And Lomb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,732,415Topical treatment or prevention of ocular infections► Subscribe
8,497,304Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid► Subscribe
8,252,307Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
7,282,589Acid addition salt of optically active piperidine compound and process for preparing the same► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bausch And Lomb Drugs

Country Document Number Estimated Expiration
Taiwan201038536► Subscribe
Portugal1165058► Subscribe
Japan2002540147► Subscribe
China1242013► Subscribe
European Patent Office1588702► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bausch And Lomb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0128France► SubscribePRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
C0031France► SubscribePRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/11/692/001 DU 20110518; REGISTRATION NO/DATE AT EEC: EU/1/11/692/001 DU 20110518
C0041Belgium► SubscribePRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Harvard Business School
Colorcon
Deloitte
Mallinckrodt
AstraZeneca
QuintilesIMS
Citi
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot